Autori: Ulmer Hanno
Naslov | High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study (Article) |
Autori | Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Ulmer Hanno Kwakkelstein Marthin Rancati Francesca Gastl Guenther A |
Info | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2010), vol. 95 br. 6, str. 908-913 |
Projekat | Novartis |
Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
Naslov | Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study) (Meeting Abstract) |
Autori | Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Boskovic Darinka V Griskevicius Laimonas Lejniece Sandra Spasov Emil Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Stanchev Atanas Kwakkelstein Martin Ulmer Hanno Gastl Guenther A |
Info | BLOOD, (2007), vol. 110 br. 11, str. 317A-317A |
Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |